Based on these exciting results, the FDA approved pirtobrutinib for the management of patients with R/R CLL after at least two previous treatment lines, including a covalent BTK inhibitor and BCL-2 inhibitor. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.